Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma

Anti-Cancer Drugs

Volumn 20, Issue 1, 2009, Pages 73-74

  Pintoffl, Jan ^a   Meisinger, Ines ^a   Mayer, Frank ^a   Horger, Marius ^a   Von Weyhern, Claus ^a   Kanz, Lothar ^a   Hartmann, Joerg Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEMCITABINE; IFOSFAMIDE;

ADULT; ARTICLE; CANCER RESISTANCE; CANCER SURGERY; CASE REPORT; FOLLOW UP; HEMANGIOENDOTHELIOMA; HISTOPATHOLOGY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DEOXYCYTIDINE; DOXORUBICIN; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; IFOSFAMIDE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; SCAPULA; TIME FACTORS; TREATMENT OUTCOME;

EID: 57349108046     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32831b9b0b     Document Type: Article

References (5)

1. Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anti-Cancer Drugs 2000; 11:325-329.
2. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38:556-559.
3. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 94; 3225-3229.
4. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001; 19: 3483-3489.
5. Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006; 24:249-253.